Long-Term Effects of Lifestyle Intervention and Metformin during DPP on Appendicular Lean Mass
The DOI matches its Crossref record.
Abstract
Weight loss prevents progression to diabetes but long term effects on lean mass are unknown. We determined if intensive lifestyle modification (ILS), metformin (MET) or placebo (PLB) treatment in the Diabetes Prevention Program (DPP) had differential effects on appendicular lean mass (ALM) and sarcopenic-obesity (SO) ∼16 years after DPP randomization in the DPP Outcome Study (DPPOS). During DPP, 3234 participants at high risk for diabetes were randomized to ILS, MET or PLB; 2779 continued in DPPOS and were offered modified group ILS. During DPPOS, ILS was offered additional lifestyle reinforcement semi-annually and MET received unmasked metformin. This analysis includes 1374 DPPOS participants who had dual-energy X-ray absorptiometry scans at year 12 for ALM (sum of lean mass in arms and legs). Low ALM was defined as ALM/BMI <0.789 for men or <0.512 for women. SO was defined as low ALM with BMI>30. Prevalence of low ALM and SO was compared across the 3 groups using Pearson’s chi-squared test. Logistic regression models determined the associations between treatment and low ALM or SO and between weight loss and low ALM or SO. Mean age at Y12 was 66.5 (±9.5) years. Mean time since DPP baseline was 15.6 (±0.7) years. Weight loss (DPP baseline to DPPOS Y12) did not differ by group (-4.4 kg ILS; -3.5 kg MET; -3.1 kg PLB; p=0.114). Prevalence of low ALM differed by group in men (35.7% ILS, 28.3% MET, 22.5% PLB; p=0.049) but not women (20.9% ILS, 24.8% MET, 24.1% PLB; p=0.482). In men, low ALM prevalence was higher in ILS compared with PLB (P=0.024) but not in MET vs. PLB. Prevalence of SO did not differ across groups in men (23.1% ISL, 22.0% MET, 14.1% PLB; p=0.112) or women (17.3% ILS, 20.9% MET, 20.3% PLB; p=0.492). SO prevalence was not different in ILS vs. PLB or in MET vs. PLB in men or women. More weight loss was associated with higher risk of low ALM and SO in women and men (p<0.001) independent of group. In men but not women at high risk of diabetes, lifestyle intervention to prevent diabetes may contribute to lower ALM. Disclosure: A.V. Schwartz: None. Q. Pan: None. H.P. Hazuda: None. E. Horton: Advisory Panel; Self; PTS Diagnostics, Merck & Co., Inc., Theracos, Inc.. M.A. Hoskin: None. R. Rastogi Kalyani: None. W.C. Knowler: None. A. Kriska: None. M. Schlögl: None. H. Florez: Advisory Panel; Self; Sanofi. D. Research Group: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes
Kotwal, A., Haddox, C., Block, M., & Kudva, Y. C. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000591 · Cited by 228
Immune checkpoint inhibitor-associated diabetes: a single-institution experience
Byun, D. J., Braunstein, R., Flynn, J., Zheng, J., Lefkowitz, R. A., Kanbour, S., & Girotra, M. (2020) · Diabetes Care · doi:10.2337/dc20-0609 · Cited by 64
Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019
Liu, J., Zhou, H., Zhang, Y., Fang, W., Yang, Y., Huang, Y., & Zhang, L. (2020) · Diabetes Care · doi:10.2337/dc20-0459 · Cited by 55
Metadata
- Authors
- SCHWARTZ, A. V., PAN, Q., HAZUDA, H. P., HORTON, E., HOSKIN, M. A., KALYANI, R. R., KNOWLER, W. C., KRISKA, A., SCHLÖGL, M., FLOREZ, H., & DPP RESEARCH GROUP
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-07-01
- Volume
- 67
- Issue
- Supplement_1
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2809039315
- Cited by
- 33
- References
- 0
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Effects of Lifestyle Intervention and Metformin during DPP on Appendicular Lean Mass. https://app.cochat.ai/papers/10.2337/db18-1471-p
- The paper
- SCHWARTZ, A. V., PAN, Q., HAZUDA, H. P., HORTON, E., HOSKIN, M. A., KALYANI, R. R., KNOWLER, W. C., KRISKA, A., SCHLÖGL, M., FLOREZ, H., & DPP RESEARCH GROUP. (2018). Long-Term Effects of Lifestyle Intervention and Metformin during DPP on Appendicular Lean Mass. Diabetes. https://doi.org/10.2337/db18-1471-p
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.